• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Ophthalmol . The characteristics of acute macular neuroretinopathy following COVID-19 infection

tetano

Editor, Senior Moderator
BMC Ophthalmol


. 2024 Jan 10;24(1):19.
doi: 10.1186/s12886-024-03283-2. The characteristics of acute macular neuroretinopathy following COVID-19 infection

Hui Feng[SUP] 1 [/SUP], Meng Zhao[SUP] 1 [/SUP], Jing Mo[SUP] 1 [/SUP], Xusheng Cao[SUP] 1 [/SUP], Weixin Chen[SUP] 1 [/SUP], Hong Wang[SUP] 2 [/SUP]



Affiliations
Abstract

Background: In this study, we report a case series of acute macular neuroretinopathy (AMN) associated with COVID-19 infection.
Methods: This retrospective observational study was conducted at Beijing Tongren Hospital. We reviewed patients who were diagnosed with AMN within one month of testing positive for COVID-19 using real-time reverse transcription-polymerase chain reaction (RT-PCR).
Results: A total of 11 AMN patients (20 eyes) were included in the study. The mean age was 33.8 ± 12.6 years. The average interval between a positive COVID-19 PCR test and the onset of ocular symptoms was 2.8 ± 2.5 days. The mean follow-up period for the patients was 12.5 ± 3.8 weeks. Imaging characteristics of AMN patients following COVID-19 infection included areas of low reflectivity on near-infrared reflectance (NIR) imaging, hyperreflective lesions at the level of the outer plexiform layer (OPL) and outer nuclear layer (ONL) and disruption of the ellipsoid zone (EZ) on spectral domain optical coherence tomography (SD-OCT) B-scans. Visual field examinations revealed parafoveal scotomas that closely corresponded to the clinical lesions. Optical coherence tomography angiography (OCT-A) demonstrated impaired perfusion in the deep retinal vascular plexus. Fluorescein angiography (FA), indocyanine green angiography (ICGA), and spontaneous fundus autofluorescence showed no significant abnormalities. During follow-up, partial improvement in retinal lesions was observed in NIR imaging and SD-OCT in some patients, but a proportion of patients still exhibited persistent retinal damage and no improvement in visual field scotomas.
Conclusion: COVID-19-related AMN share similar clinical and imaging features with AMN due to other causes, as evidenced by the persistent presence of visual field scotomas over a longer duration.
Trail registration: https://www.chictr.org.cn/ ; identifier: ChiCTR2100044365.

Keywords: Acute macular neuroretinopathy; COVID-19; Optical coherence tomography; Optical coherence tomography angiography; Severe acute respiratory syndrome coronavirus-2; Visual field.

 
Back
Top Bottom